Clinical Pharmacology

Selected news for the healthcare topic - Clinical Pharmacology, collected since 10/2017. This healthcare topic shares news with Food and Drug Administration, Heart Disease, Pfizer, Infectious Disease, Clinical Research and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/19/2021 Therapeutic Drug Monitoring Market Sales and Revenue Analysis by Type, Trend, Application, Manufactures, Regions and Forecasts From 2016- 2026 knnit.com The global Therapeutic Drug Monitoring market was valued at USD 1.21 Billion in 2018 and is expected to reach USD 1.91 Billion by year 2026, at a CAGR of 5.8 %. The study covers Therapeutic drug monitoring – a branch of clinical pharmacology and chemistry, which measures and maintains specific ingredient concentration levels in body fluids or blood streams. The monitoring process is aimed at refining patient care for better outcomes ...
9/18/2021 Duke Event Calendar duke.edu ... on Terrorism and Homeland Security", "Triangle Institute for Security Studies (TISS)"], "short"= "academic_calendars", "long"= "Academic Calendars", "display"= false), ("list"= ["Department of Anesthesiology", "Division of Cardiology", "Division of Cardiovascular and Thoracic Surgery", "Division of Clinical Pharmacology ", "Division of Endocrinology, Metabolism, and Nutrition", "Division of Gastroenterology", "Division of General Internal Medicine", "Division of General Surgery", "Division of Geriatrics", "Division of Hematologic Malignancies and Cellular Therapy", "Division of Hematology", "Division of Infectious ...
9/18/2021 Duke Event Calendar duke.edu ... on Terrorism and Homeland Security", "Triangle Institute for Security Studies (TISS)"], "short"= "academic_calendars", "long"= "Academic Calendars", "display"= false), ("list"= ["Department of Anesthesiology", "Division of Cardiology", "Division of Cardiovascular and Thoracic Surgery", "Division of Clinical Pharmacology ", "Division of Endocrinology, Metabolism, and Nutrition", "Division of Gastroenterology", "Division of General Internal Medicine", "Division of General Surgery", "Division of Geriatrics", "Division of Hematologic Malignancies and Cellular Therapy", "Division of Hematology", "Division of Infectious ...
9/18/2021 Duke Event Calendar duke.edu ... on Terrorism and Homeland Security", "Triangle Institute for Security Studies (TISS)"], "short"= "academic_calendars", "long"= "Academic Calendars", "display"= false), ("list"= ["Department of Anesthesiology", "Division of Cardiology", "Division of Cardiovascular and Thoracic Surgery", "Division of Clinical Pharmacology ", "Division of Endocrinology, Metabolism, and Nutrition", "Division of Gastroenterology", "Division of General Internal Medicine", "Division of General Surgery", "Division of Geriatrics", "Division of Hematologic Malignancies and Cellular Therapy", "Division of Hematology", "Division of Infectious ...
9/14/2021 Lengo Therapeutics Announces Expansion of its Executive Leadership Team with Appointments in R&D, CMC and Finance Business Wire ... Chief of Development at Lengo Therapeutics. He has over 30 years of experience and has advised biopharmaceutical companies and the National Institutes of Health in the areas of drug discovery, pharmacokinetics, drug metabolism and clinical pharmacology . Previously, he served as Global Head of Pharmacokinetics and Drug Metabolism at Amgen, the world’s largest biotechnology company. Prior to Amgen, Paul served as Executive Director of Preclinical Drug Metabolism at Merck Research ...
9/10/2021 As delta surges among unvaccinated, how a focus on science can counter misinformation expressinformer.com ... Goldman, host of White Coat, Black Art and The Dose. Vohra-Miller is the Toronto-based founder of Unambiguous Science, a platform that aims to make science accessible. She also has a background in clinical pharmacology and toxicology. Right now, she said, unvaccinated people likely have complex and very specific concerns. “People who had very minor questions that they wanted to ask, those people have already been vaccinated.” These ...
9/10/2021 Roadmap to 2030 for New Drug Evaluation in Older Adults - 03/23/2021 - 03/23/2021 fda.gov Workshop - Date: - March 23, 2021 - Time: - 10:00 AM - 4:30 PM ET Sponsored by the Office of Clinical Pharmacology OTS, CDER, U.S. Food and Drug Administration (FDA) The U.S. Food and Drug Administration (FDA) will host a virtual public workshop entitled “Roadmap to 2030 for New Drug Evaluation in Older Adults” on March 23, 2021. This workshop will bring together stakeholders from academia, industry, and regulatory agencies in a virtual ...
9/8/2021 RASAGILINE tablet [Teva Pharmaceuticals USA, Inc.] National Institutes of Health ... Taking Ciprofloxacin or Other CYP1A2 Inhibitors Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of rasagiline 0.5 mg once daily [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 ), and Clinical Pharmacology ( 12.3 )]. 2.3 Patients with Hepatic Impairment Patients with mild hepatic impairment should not exceed a dose of rasagiline 0.5 mg once daily. Rasagiline should not be used in patients with moderate or severe hepatic ...
9/8/2021 FLUCONAZOLE tablet [PD-Rx Pharmaceuticals, Inc.] National Institutes of Health ... study. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as cisapride, astemizole, erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and PRECAUTIONS .) WARNINGS (1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily ...
9/8/2021 GEMFIBROZIL tablet [Camber Pharmaceuticals, Inc.] National Institutes of Health ... in water and acid is 0.0019% and in dilute base it is greater than 1%. The melting point is 58° – 61°C. Gemfibrozil is a white solid which is stable under ordinary conditions. CLINICAL PHARMACOLOGY Gemfibrozil is a lipid regulating agent which decreases serum triglycerides and very low density lipoprotein (VLDL) cholesterol, and increases high density lipoprotein (HDL) cholesterol. While modest decreases in total and low density lipoprotein (LDL ...
9/8/2021 GEMFIBROZIL tablet [XLCare Pharmaceuticals, Inc.] National Institutes of Health ... in water and acid is 0.0019% and in dilute base it is greater than 1%. The melting point is 58° – 61°C. Gemfibrozil is a white solid which is stable under ordinary conditions. CLINICAL PHARMACOLOGY Gemfibrozil is a lipid regulating agent which decreases serum triglycerides and very low density lipoprotein (VLDL) cholesterol, and increases high density lipoprotein (HDL) cholesterol. While modest decreases in total and low density lipoprotein (LDL ...
9/8/2021 FLUCONAZOLE tablet [PD-Rx Pharmaceuticals, Inc.] National Institutes of Health ... study. Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as cisapride, astemizole, erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and PRECAUTIONS .) WARNINGS (1) Hepatic injury: Fluconazole should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities primarily ...
9/8/2021 DUTASTERIDE capsule, liquid filled [Camber Pharmaceuticals, Inc.] National Institutes of Health ... of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing dutasteride to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology ( 12.3 )] . 7.2 Alpha Adrenergic AntagonistsThe administration of dutasteride in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha adrenergic antagonist. The effect of administration of tamsulosin ...
9/8/2021 LOVASTATIN tablet [PD-Rx Pharmaceuticals, Inc.] National Institutes of Health ... WARNINGS , Myopathy/Rhabdomyolysis ). Danazol, Diltiazem, Dronedarone, or Verapamil: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol, diltiazem, dronedarone or verapamil particularly with higher doses of lovastatin (see WARNINGS , Myopathy/Rhabdomyolysis ; CLINICAL PHARMACOLOGY , Pharmacokinetics ). Amiodarone: The risk of myopathy/rhabdomyolysis is increased when amiodarone is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS , Myopathy/Rhabdomyolysis ). Coumarin Anticoagulants: In a ...
9/8/2021 AZILECT (rasagiline mesylate) tablet [Teva Neuroscience, Inc.] National Institutes of Health ... Taking Ciprofloxacin or Other CYP1A2 Inhibitors Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of AZILECT 0.5 mg once daily [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 ), and Clinical Pharmacology ( 12.3 )]. 2.3 Patients with Hepatic Impairment Patients with mild hepatic impairment should not exceed a dose of AZILECT 0.5 mg once daily. AZILECT should not be used in patients with moderate or severe hepatic ...
9/8/2021 DUTASTERIDE capsule, liquid filled [XLCare Pharmaceuticals, Inc.] National Institutes of Health ... of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing dutasteride to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology ( 12.3 )] . 7.2 Alpha Adrenergic AntagonistsThe administration of dutasteride in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha adrenergic antagonist. The effect of administration of tamsulosin ...
9/8/2021 PDF Download# The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing Read >book *ePub | by Multi | Sep, 2021 | Medium Ebook PDF The Top 100 Drugs: Clinical Pharm a cology and Practical Prescribing EBOOK ONLINE DOWNLOADHello Friends, If you want to download free Ebook, you are in the right place to download Ebook. Ebook The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing EBOOK ONLINE DOWNLOAD in English is available for free here, Click on the download LINK below to download Ebook The Top 100 Drugs: Clinical Pharmacology and ...
9/7/2021 ONDANSETRON tablet, orally disintegrating [PD-Rx Pharmaceuticals, Inc.] National Institutes of Health ... treatment [see Warnings and Precautions (5.3) ] . 7.2 Drugs Affecting Cytochrome P-450 Enzymes Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver [see Clinical Pharmacology (12.3) ] . Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. In ...
9/7/2021 Ranitidine may not lead to significant increase in N-nitrosodimethylamine in healthy adults 2minutemedicine.com ... In this randomized controlled trial, 18 healthy adults aged 28-43 were fasted overnight and received either ranitidine (300mg) or placebo alongside a breakfast high or low in nitrite. The study was conducted in a clinical pharmacology unit in West Bend, Wisconsin, during the months of June and July of 2020. Participants who consumed nicotine-containing products, had significant past medical history, or had used any prescription of non-prescription medication ...
9/7/2021 PROPRANOLOL HYDROCHLORIDE tablet [Preferred Pharmaceuticals Inc.] National Institutes of Health ... stearic acid.Propranolol Hydrochloride Tablets, USP 10 mg and 80 mg also contain FD&C Yellow No. 6.Propranolol Hydrochloride Tablets, USP 20 mg and 40 mg also contain FD&C Blue No. 1. CLINICAL PHARMACOLOGY General Propranolol is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor agonist agents for available receptor sites. When access to beta ...